Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases

Abstract

Abstract. The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively. According to the Hans algorithm, 71 patients (79.8%) were classified into the non-germinal center B cell-like (non-GCB) group, indicating a post-germinal center origin of PCNSL. The median follow-up time of 73 patients was 13 months [95% confidence interval (CI), 10.93-15.08]. The median overall survival (OS) time was 45.3 months (95% CI, 25.01-65.59) and the median progression-free survival (PFS) time was 30.0 months (95% CI, 13.43-46.57). Age (>60 years) was associated with a shorter OS time (P=0.009). Ki-67 (cutoff point 90%) was associated with shorter OS (P=0.037) and shorter PFS (P=0.039) times. No other immunohistochemical markers were associated with prognosis. On multivariate analysis, age (>60 years) was associated with shorter OS time (P=0.038), but immunophenotype and expression status of Ki-67, CD10, BCL-6 and BCL-2 did not predict prognosis. In conclusion, high Ki-67 expression may predict poor prognosis in PCNSL. The present study was limited by its sample size and short follow-up time. This requires more evidence to further clinical study.

Diffuse large B-cell lymphoma variants: an update

“…Most cases have a non-germinal B-cell immunophenotype with MUM-1/ IRF-4 and BCL-6 often positive. 76,77 c-MYC is positive in 70-80% of cases and BCL-2 in about 75% of cases. 76,77 EZH2 is expressed, but without evidence of gene mutation.…”

“…76,77 c-MYC is positive in 70-80% of cases and BCL-2 in about 75% of cases. 76,77 EZH2 is expressed, but without evidence of gene mutation. 75 PD-L1 is positive in approximately 30% of cases 78 CD10 is positive in less than 20% of cases, CD30 is positive rarely, and CD138, T-cell markers and EBER1 are negative.…”

“…75 PD-L1 is positive in approximately 30% of cases 78 CD10 is positive in less than 20% of cases, CD30 is positive rarely, and CD138, T-cell markers and EBER1 are negative. 1,76 Cytogenetics and molecular Chromosomal alterations involving 9p21.3, 6p, 6q, chromosome 12, 18q21.33-23, and 10q23.2 have been shown. 1,79 Isolated MYC, BCL2 or BCL6 rearrangements are uncommon, but have been reported at low frequency.…”

RETRACTED ARTICLE: Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1

“…The Raf-1 protein staining rate was presented as the percentage of Raf-1 positive cells in a whole field of cells. The number of positive cells over 30% was considered to be positive (+) and the number of positive cells less than 30% was considered to be negative [28].…”

Undifferentiated sinonasal malignant melanoma: A case report

“…Immunohistochemistry was performed using the ChemMate Envision kit including secondary antibody (cat. no., DAKOK500711; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), according to the manufacturer's protocol (7). Sections were deparaffinized in xylene and dehydrated with descending alcohol series.…”